EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Dual Antiplatelet Therapy or Aspirin after Coronary Bypass Surgery

Yujun He

New England Journal of Medicine · 26.03.2026 · 394 (12) · 1243-1244

DOI: 10.1056/nejmc2600235 ↗

Kurz gefasst

Leserbrief in der Zeitschrift New England Journal of Medicine, erschienen am 26.03.2026. Verfasst von Yujun He. Beteiligte Einrichtung: Taizhou Hospital of Zhejiang Province, Taizhou, China. Die Arbeit nennt 5 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To the Editor: In their article on the TACSI trial (Dec. 11 issue) 1 regarding the use of ticagrelor plus aspirin or aspirin alone after coronary-artery bypass grafting (CABG), Jeppsson and colleagues have overlooked two critical confounders that may have obscured the true biologic efficacy of ticagrelor. First, the effect of the concomitant use of oral anticoagulants was underappreciated. At 1 year, 12.8% of the patients in the group receiving dual antiplatelet therapy and 11.5% of those in the monotherapy group were also receiving oral anticoagulants. Thus, a subset of patients were effectively receiving high-risk triple therapy, which could have confounded . . .

Autor:innen und Institutionen

  • Taizhou Hospital of Zhejiang Province, Taizhou, China.

Zitieren

APA

He, Y. (2026). Dual Antiplatelet Therapy or Aspirin after Coronary Bypass Surgery. New England Journal of Medicine, 394(12), 1243-1244. https://doi.org/10.1056/nejmc2600235

Vancouver

He Y. Dual Antiplatelet Therapy or Aspirin after Coronary Bypass Surgery. New England Journal of Medicine. 2026;394(12):1243-1244. doi:10.1056/nejmc2600235

BibTeX
@article{He2026,
  author = {He, Yujun},
  title = {Dual Antiplatelet Therapy or Aspirin after Coronary Bypass Surgery},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {12},
  pages = {1243--1244},
  doi = {10.1056/nejmc2600235}
}
Kostenlos starten →